Chris Wynne - Concepedia

Author

Chris Wynne

Christchurch Clinical Studies Trust

Also Known As

Chris J. Wynne, Chris Wynne

Publications

1.9K

Citations

H-Index

Concepts

All Affiliations

Christchurch Clinical Studies Trust Westmead Hospital Dunedin Public Hospital Peter MacCallum Cancer Centre Sir Charles Gairdner Hospital

About

Chris Wynne is an author at Christchurch Clinical Studies Trust specializing in medicine, oncology, and radiation oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	9	9	1.1K
2	Pharmacology	3	3	90
3	Health Sciences	2	2	103
4	Immunology	1	1	51
5	Pathology	1	1	73

Chris Wynne

Publications

1.8K

Citations

H-Index

Page 1

	Year	Citations
Natural History of Rising Serum Prostate-Specific Antigen in Men With Castrate Nonmetastatic Prostate Cancer Matthew R. Smith, Fairooz F. Kabbinavar, Fred Saad, Journal of Clinical Oncology	2005	493
Short-term neoadjuvant androgen deprivation and radiotherapy for locally advanced prostate cancer: 10-year data from the TROG 96.01 randomised trial James W. Denham, Allison Steigler, David S. Lamb, The Lancet Oncology UrologyGenitourinary CancerMedicine10-Year DataAdvanced Prostate Cancer	2011	443
Short-term androgen deprivation and radiotherapy for locally advanced prostate cancer: results from the Trans-Tasman Radiation Oncology Group 96.01 randomised controlled trial James W. Denham, Allison Steigler, David S. Lamb, The Lancet Oncology UrologyRadiation MedicineRadiation TherapyMedicineShort-term Androgen Deprivation	2005	376
Comparison of Subcutaneous and Intravenous Administration of Trastuzumab: A Phase I/Ib Trial in Healthy Male Volunteers and Patients With HER2‐Positive Breast Cancer Chris Wynne, Vernon Harvey, Christian Schwabe, The Journal of Clinical Pharmacology	2012	126
Is there more than one proctitis syndrome? A revisitation using data from the TROG 96.01 trial Anne Capp, Mario Inostroza-Ponta, Dana Bill, Radiotherapy and Oncology Clinical FindingImmunodeficienciesDiagnosisPathologyCommon Diseases	2008	73
A comparison of proton and megavoltage X-ray treatment planning for prostate cancer Michael J. Lee, Chris Wynne, Steve Webb, Radiotherapy and Oncology Health SciencesMedicineBrachytherapyRadiation Therapy PlanningProton Therapy	1994	52
Delayed rectal and urinary symptomatology in patients treated for prostate cancer by radiotherapy with or without short term neo-adjuvant androgen deprivation David Christie, James W. Denham, Allison Steigler, Radiotherapy and Oncology Surgical OncologyUrologyDelayed RectalGenitourinary CancerMedicine	2005	51
First‐in‐human phase 1 trial evaluating safety, pharmacokinetics, and pharmacodynamics of NLRP3 inflammasome inhibitor, GDC‐2394, in healthy volunteers Fei Tang, Rebecca Kunder, Tom Chu, Clinical and Translational Science ImmunologyPharmacotherapyPd BiomarkersInflammationClinical Trials	2023	51
Development of a Subcutaneous Fixed‐Dose Combination of Pertuzumab and Trastuzumab: Results From the Phase Ib Dose‐Finding Study Whitney P. Kirschbrown, Chris Wynne, Matts Kågedal, The Journal of Clinical Pharmacology	2018	36
Acceptability of short term neo-adjuvant androgen deprivation in patients with locally advanced prostate cancer David S. Lamb, James W. Denham, Hedy Mameghan, Radiotherapy and Oncology UrologyGenitourinary CancerMedicineCancer ManagementAdvanced Prostate Cancer	2003	35

Page 1